Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.79 |
| ▸ | IDO1 | P14902 | 2/20 | 0.65 |
| ▸ | AGXT | P21549 | 2/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22873 | 0.93 | MAOB (0.70) | MAOBIDO1AGXTBCHEABCB1 | |
| SCHEMBL14547318 | 0.92 | MAOB (0.81) | MAOBIDO1AGXTBCHEABCB1 | |
| SCHEMBL791569 | 0.89 | MAOB (1.00) | MAOBBCHEABCB1HTR1ADRD2 | |
| SCHEMBL171916 | 0.87 | MAOB (0.73) | MAOBIDO1AGXTBCHEMRGPRX4 | |
| SCHEMBL15730033 | 0.87 | MAOB (0.62) | MAOBIDO1AGXTBCHEABCB1 | |
| SCHEMBL16710547 | 0.87 | MAOB (0.71) | MAOBIDO1AGXTBCHEABCB1 | |
| SCHEMBL13332739 | 0.86 | MAOB (0.70) | MAOBBCHEABCB1MRGPRX4 | |
| SCHEMBL920589 | 0.86 | MAOB (0.67) | MAOBIDO1AGXTBCHEABCB1 | |
| SCHEMBL21260547 | 0.86 | MAOB (0.73) | MAOBIDO1AGXTBCHEABCB1 | |
| SCHEMBL1680537 | 0.86 | MAOB (1.00) | MAOBIDO1AGXTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198754-B2 | Heat-curing epoxy resin composition containing non-aromatic ureas as accelerator | SIKA TECHNOLOGY AG (CH) | 2021-12-14 | — | — | US | disclosed |
| US-20190002626-A1 | HEAT-CURING EPOXY RESIN COMPOSITION CONTAINING NON-AROMATIC UREAS AS ACCELERATOR | SIKA TECHNOLOGY AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-9196860-B2 | Compounds for triplet-triplet annihilation upconversion | UNIVERSAL DISPLAY CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140151646-A1 | COMPOUNDS FOR TRIPLET-TRIPLET ANNIHILATION UPCONVERSION | UNIVERSAL DISPLAY CORPORATION | 2014-06-05 | — | — | US | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | MAOB 1392/4885IDO1 1055/4885AGXT 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.